Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Real-world efficacy and safety of venetoclax-based therapy in israeli patients with CLL/SLL: Results from the reveal study

Yair Herishanu, Neta Goldschmidt, Liron Hofstetter et al. Nov 03, 2025 pp. 3893-3893 10.1182/blood-2025-3893

Abstract Introduction Venetoclax-based therapy has significantly altered the treatment landscape for chronic lymphocytic...

#asheducation: Data and insights on social media's unique power for hematology education

Nathalie Van Havre, Talia Genova, Aakanksha Angra Nov 03, 2025 pp. 4642-4642 10.1182/blood-2025-4642

Abstract Social media microlearning has emerged as an effective approach to medical education, offering concise, accessible educational cont...

Phase II trial of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone in multiple myeloma following BCMA CAR T-cell therapy

Benjamin Derman, Jennifer Cooperrider, Frank Wen et al. Nov 03, 2025 pp. 5832-5832 10.1182/blood-2025-5832

Abstract Introduction: Treatment options are limited for patients who multiple myeloma (MM) relapses after B-cell maturation antigen (BCMA)-...

Clinical experience and safety of venetoclax in the treatment of patients with chronic lymphocytic leukemia in second and subsequent lines of therapy: Real-world data fron hemato-oncology centers  of slovakia

Juliana Holasova, Andrej Vranovsky, Ludmila Demitrovicova et al. Nov 03, 2025 pp. 7424-7424 10.1182/blood-2025-7424

Abstract Introduction: The treatment landscape for chronic lymphocytic leukemia (CLL) has significantly evolved in recent years, transitioni...

Feasibility of the edmonton symptom assessment system (ESAS) score as patient-reported outcomes (PROs) assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor therapy: A pilot Study

Maria Perusini, Noora Obaidallah, Yael Morgenstern et al. Nov 03, 2025 pp. 7294-7294 10.1182/blood-2025-7294

Abstract Introduction A substantial proportion of chronic myeloid leukemia (CML) patients experience tyrosine kinase inhibitor (TKI)-related...

Retrospective analysis in mortality from phlebitis/thrombophlebitis and atrial fibrillation/flutter in u.S. adults aged ≥45 years from 1999–2023: A CDC wonder study

Hakim Wazir, Amna Amjad, Shahreena Athar Siddiqui et al. Nov 03, 2025 pp. 8007-8007 10.1182/blood-2025-8007

Abstract Background: Atrial Fibrillation (AF) is characterized by irregular and often rapid heartbeats due to disorganized electrical activi...

The c-terminal to lish (CTLH) E3 ligase complex modulates myeloma glucocorticoid sensitivity by regulating nfkb signaling

Amin Sobh, Emilie Bonilla, Alberto Riva et al. Nov 03, 2025 pp. 2145-2145 10.1182/blood-2025-2145

Abstract Background: Glucocorticoids remain a cornerstone of frontline therapy for multiple myeloma (MM), yet resistance to these agents—par...

Single day long read whole genome sequencing for Acute Myeloid Leukemia

Parth Shah, Sophie Deharvengt, Lauren Wainman et al. Nov 03, 2025 pp. 5286-5286 10.1182/blood-2025-5286

Abstract Introduction: Acute myeloid leukemia (AML) is considered a medical emergency and its management has evolved dra...

Senescence-prone immune cell subsets expand in the aged environment

Yuki Okamura, Teh-Wei Wang, Makoto Nakanishi Nov 03, 2025 pp. 1225-1225 10.1182/blood-2025-1225

Abstract Cellular senescence is an intriguing phenomenon in which cells enter cell cycle arrest and obtain peculiar properties upon encounte...

Impact of secondary FVIII prophylaxis on joint bleeding and arthropathy in a Hemophilia A mouse model lacking inhibitor response

Lara Monica, Joyce Kimenai, Olga Oleshko et al. Nov 03, 2025 pp. 13-13 10.1182/blood-2025-13

Abstract Introduction: Hemophilia A (HA) is a severe bleeding disorder complicated by arthropathy of the large joints, due to synovial iron...

Machine learning based survival prediction of DLBCL: Using multimodal data.

Fahad Ahmed, Zachary Frosch, Rashmi Khanal et al. Nov 03, 2025 pp. 7068-7068 10.1182/blood-2025-7068

Abstract Background: Diffuse-large B-cell lymphoma (DLBCL) is a heterogeneous disease with outcomes influenced by various clinical and molec...

Functional genomics studies identify determinants of response vs. resistance to pharmacological inhibitors of KRAS in multiple myeloma

Torsten Steinbrunn, Arnold Bolomsky, Ryosuke Shirasaki et al. Nov 03, 2025 pp. 327-327 10.1182/blood-2025-327

Abstract Up to 50% of multiple myeloma (MM) patients harbor mutations of KRAS or NRAS. Pharmacologic inhibitors targeting specific KRAS muta...

Automated multi-source data consensus classification of low-frequency variants in hematologic malignancies using transparent artificial intelligence

Niroshan Nadarajah, Nanditha Mallesh, Kathrin Hildebrand et al. Nov 03, 2025 pp. 2576-2576 10.1182/blood-2025-2576

Abstract Background: Evaluating the pathogenicity of a variant is challenging given the plethora of types of genetic evidence that laborator...

Excellent long-term outcomes after alemtuzumab-based hematopoietic cell transplantation (HCT) for severe aplastic anemia (SAA) and inherited bone marrow failure syndromes (IBMF): A 25-year British society of blood and marrow transplantation and cellular therapy (BSBMTCT) retrospective analysis of 1754 patients from the United Kingdom (UK)

Austin Kulasekararaj, Kanchan Rao, Rachel Pearce et al. Nov 03, 2025 pp. 984-984 10.1182/blood-2025-984

Abstract Background: Allogeneic stem cell transplantation (HCT) is a curative option for patients with acquired severe aplastic anemia (SAA)...

Disrupting the global CAR T paradigm from the Middle East: Ultra-fast swift CAR T and scalable point-of-care manufacturing of autologous CAR T cells for hematologic malignancies

Farhatullah Syed, Walid Warda, Hanan Alqudairy et al. Nov 03, 2025 pp. 2406-2406 10.1182/blood-2025-2406

Abstract Background and Aims: CAR T-cell therapy has revolutionized treatment for CD19+ blood cancers, but conventional manufacturing is cos...

Acute Myeloid Leukemia and sepsis-related mortality in the United States (U.S.) older adults: Nationwide trends and disparities over 25 years (1999 – 2023)

hareem tahir, Muhammad Zahid Anwar, Ramesha Tahir et al. Nov 03, 2025 pp. 1627-1627 10.1182/blood-2025-1627

Abstract Introduction Acute myeloid leukemia (AML) is a rapidly progressive hematological malignancy characterized by the clonal proliferati...

Machine Learning–Based risk stratification in patients with direct anti‑xa Inhibitors–Related bleeding treated with four‑factor prothrombinex complex concentrate (4F-PCC)

Chun Fung SIN, Yuen Ting Sin, Chung Yin Ha et al. Nov 03, 2025 pp. 4910-4910 10.1182/blood-2025-4910

Abstract Introduction: Patients taking direct oral anticoagulants (DOACs), including direct anti-Xa inhibitors, have risk of major bleeding...

Addition of venetoclax to hypomethylating agent offers limited incremental benefit for patients with treatment-naïve TP53-mutated myelodysplastic syndromes

Michael Canonico, Parth Patel, Hayley Hawkins et al. Nov 03, 2025 pp. 7388-7388 10.1182/blood-2025-7388

Abstract Introduction Myelodysplastic syndromes (MDS) with TP53 mutations (mTP53) are characterized by suboptimal treatment response and dis...

STAG2 mutation preserves a stem cell phenotype in FLT3-ITD-mediated MDS to leukemia transformation

Jane J Xu, Yi Chen, John Pantazi et al. Nov 03, 2025 pp. 3242-3242 10.1182/blood-2025-3242

Abstract Acute myeloid leukemia with myelodysplastic related changes (AML-MRC) subtype is diagnosed when patients present leukemia with know...

A retrospective population-based study of long-term treatments and outcomes inwaldenstrom macroglobulinemia in Ontario, Canada

Arjun Pandey, Barbara Gunka, Mohammed Aljama et al. Nov 03, 2025 pp. 3612-3612 10.1182/blood-2025-3612

Abstract Introduction: Waldenstrom Macroglobulinemia (WM) is a rare B-cell malignancy characterized by periods of low burden disease not req...

Bone and region-specific targeting of SCF and CXCL12 in stromal niche cells reveals local and lineage-specific regulation of terminal hematopoiesis

Yanan Zhang, Jun Sun, Matthew Greenblatt et al. Nov 03, 2025 pp. 430-430 10.1182/blood-2025-430

Abstract LepR+ stromal cells in the bone marrow microenvironment produce essential regulatory factors like SCF-which promotes hematopoietic...

Additional genetic abnormalities (AGA) and microhomology end-joining DNA repair (MMEJ) signatures influence the outcome of newly diagnosed chronic phase (CP) CML: Ancillary study of the Trial of imatinib after ponatinib induction (TIPI)

Franck Nicolini, Françoise Huguet, Aude Charbonnier et al. Nov 03, 2025 pp. 3773-3773 10.1182/blood-2025-3773

Abstract Introduction: Recently, the presence of a variety of AGA to the BCR-ABL1 oncogene in CP-CML has been described to impair the prognos...

Beyond ECOG: Assessment of physical function enhances risk stratification prior to CAR-T cell therapy

Alessandra Holzem, Michael Ingrisch, Anna Magee et al. Nov 03, 2025 pp. 6331-6331 10.1182/blood-2025-6331

Abstract Background The Eastern Cooperative Oncology Group performance status (ECOG PS) represents the standard for asse...

Combined TCR-seq and single-cell RNA-seq reveal distinct origins for antiviral immunity after post-transplant cyclophosphamide and tac/MTX gvhd prophylaxis: Results from the BMT CTN 1801 study

Steven Siegel, Susan DeWolf, Joseph Schmalz et al. Nov 03, 2025 pp. 818-818 10.1182/blood-2025-818

Abstract Background: A randomized multicenter trial (BMT CTN 1703) demonstrated that after reduced intensity conditioning HCT, PT-Cy-based G...

The antibiotic linezolid targets the Jak2V617F mutation in polycythemia vera.

Huihui Li, Christoph Schaniel, Anisa Azatovna Gumerova et al. Nov 03, 2025 pp. 642-642 10.1182/blood-2025-642

Abstract Current treatment options for polycythemia vera (PV) patients suppress excessive hematopoiesis, but lack specificity against JAK2V6...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page